自拍无码精品一区二区|亚洲А∨天堂久久精品|国产日韩欧美一区二区视|亚洲av高清dvd丝袜|中文一级无码黄片精品视频|亚洲无码网站在线免费观看|免费无码又爽又刺激又污又黄|成人免费无码婬片在线观看免费

  • <tfoot id="icskm"></tfoot>
  • <code id="icskm"><xmp id="icskm"></xmp></code>
  • <li id="icskm"><input id="icskm"></input></li>
    <code id="icskm"></code>
  • <cite id="icskm"><center id="icskm"></center></cite><button id="icskm"><bdo id="icskm"></bdo></button><code id="icskm"></code>
  • <cite id="icskm"><pre id="icskm"></pre></cite>
    <button id="icskm"></button>
  • <rt id="icskm"><pre id="icskm"></pre></rt>
    <cite id="icskm"></cite>
    <li id="icskm"></li>
    <button id="icskm"><input id="icskm"></input></button>
  • 159-2642-3062 027-65317797
    服務熱線(工作日:9:00-17:30)

    瀏覽量: 256

    • 產(chǎn)品名稱: Research Grade Reslizumab ( 瑞利珠單抗 )
    • 產(chǎn)品貨號: CSD00181
    • 貨期: 現(xiàn)貨
    • 價格與訂購: 2480
    • 數(shù)量:
      庫存: 100
    • 規(guī)格: 100μg
    • 產(chǎn)品信息
    • 如何訂購
      貨號(Catalog No.)
      CSD00181
      通用名INN
      Reslizumab
      純度(Purity)
      >95%
      濃度( Concentration)
      1mg/ml
      Formulation
      PBS buffer PH7.5
      Source
      CHO cells
      內(nèi)毒素(Endotoxin level)
      Please contact with the lab for this information.
      產(chǎn)品描述(Description)
      Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
      別名(Alternative names)
      CDP-835,JES1-39D10,SCH55700
      靶點;物種(Specificity target name;species)
      Humanized
      活性研究(體外/體內(nèi)研究)(Activity in vitro)
      Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.
      種類(Species)
      Chimeric
      受體鑒定(Receptor identification)
      IgG4-nd
      CAS
      241473-69-8
      存儲條件(Storage)
      Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
      Store at +4°C short term (1-2 weeks).
      Store at -20 °C 12 months.
      Store at -80°C long term.
      Note
      For research use only .
    雷州市| 赞皇县| 黄山市| 金坛市| 高碑店市| 双流县| 瑞昌市| 八宿县| 祁门县| 太谷县| 永和县| 彩票| 兴文县| 昆明市| 岳阳县| 平陆县| 合山市| 靖边县| 遂平县| 中方县| 兴海县| 广宗县| 乡宁县| 四平市| 五华县| 四会市| 长沙市| 博客| 鲁甸县| 乐昌市| 项城市| 乌拉特后旗| 石首市| 柏乡县| 垦利县| 隆林| 铁岭市| 曲水县| 奉节县| 加查县| 都昌县|